Literature DB >> 33902104

Natural History of Patients Diagnosed with Cardiac Sarcoidosis at Left Ventricular Assist Device Implantation or Cardiac Transplantation.

Tyler J Schmidt1, Andrew N Rosenbaum2, Nikhil Kolluri1, John M Stulak3,4, Richard C Daly3,4, John A Schirger2,4, Mohamed Y Elwazir2, Suraj Kapa2, Leslie T Cooper5, Lori A Blauwet2.   

Abstract

To our knowledge, natural history has not been reported for cardiac sarcoidosis (CS) diagnosed by pathologic evaluation of the apical core at left ventricular assist device (LVAD) implantation or cardiac transplantation. We retrospectively identified 232 consecutive patients meeting CS criteria. Of these patients, 54 were diagnosed by pathologic confirmation of CS, 10 after evaluation of the apical core (LVAD implant) or explanted heart (transplant). We compared clinical characteristics at initial evaluation and outcomes for these 10 patients with those of 10 patients with known CS before LVAD implant/transplant. In the study group, five patients (50%) had confirmed extracardiac sarcoidosis before LVAD implant/transplant; five had not been diagnosed with sarcoidosis. Mean (standard deviation) left ventricular ejection fraction at initial evaluation was 23% (16%), and left ventricular end-diastolic dimension was 61 (10) mm. Four patients died during follow-up; however, no survival difference was found for the 10 patients diagnosed incidentally and the group with a previous diagnosis or institutional LVAD/transplant cohorts. Patients diagnosed with CS on pathological examination of the apical core/explanted heart may have severe dilated cardiomyopathy as the initial presentation. Outcomes for patients with CS after advanced heart failure therapies may be comparable with those of non-CS patients.
Copyright © ASAIO 2020.

Entities:  

Year:  2021        PMID: 33902104     DOI: 10.1097/MAT.0000000000001262

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  2 in total

1.  Outcomes after heart transplantation in patients with cardiac sarcoidosis.

Authors:  Rabea Asleh; Alexandros Briasoulis; Ilias Doulamis; Hilmi Alnsasra; Aspasia Tzani; Paulino Alvarez; Toshiki Kuno; Polydoros Kampaktsis; Sudhir Kushwaha
Journal:  ESC Heart Fail       Date:  2022-01-15

Review 2.  Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.

Authors:  Nisha A Gilotra; Jan M Griffin; Noelle Pavlovic; Brian A Houston; Jessica Chasler; Colleen Goetz; Jonathan Chrispin; Michelle Sharp; Edward K Kasper; Edward S Chen; Ron Blankstein; Leslie T Cooper; Emer Joyce; Farooq H Sheikh
Journal:  J Card Fail       Date:  2021-07-11       Impact factor: 5.712

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.